Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.38 |
| ▸ | LIPA | P38571 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19169454 | 0.81 | NCF1 (0.43) | KCNH2CACNA1ILIPAHTR4 | |
| SCHEMBL8406312 | 0.80 | LIPA (0.52) | EPHX1SMN1; SMN2LIPA | |
| SCHEMBL12981142 | 0.79 | LIPA (0.39) | KCNH2CACNA1ILIPA | |
| SCHEMBL13617466 | 0.79 | SMN1; SMN2 (0.52) | EPHX1SMN1; SMN2HSD11B1EPHX2HRH3 | |
| SCHEMBL1762876 | 0.79 | SMN1; SMN2 (0.52) | EPHX1SMN1; SMN2HSD11B1EPHX2 | |
| SCHEMBL13622462 | 0.77 | EPHX1 (0.55) | EPHX1SMN1; SMN2HSD11B1EPHX2CACNA1I | |
| Hydrochloric Acid SCHEMBL3579455 | 0.77 | EPHX1 (0.50) | EPHX1SMN1; SMN2HSD11B1EPHX2 | |
| SCHEMBL4822849 | 0.77 | SMN1; SMN2 (0.60) | EPHX1SMN1; SMN2HSD11B1EPHX2HRH3 | |
| SCHEMBL14255273 | 0.76 | ITGB3 (0.37) | LIPA | |
| SCHEMBL31486529 | 0.76 | LIPA (0.46) | EPHX2LIPA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | EPHX1 1882/4885SMN1; SMN2 1733/4885HSD11B1 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.